Header Logo

Connection

ROBERT F GAGEL to Proto-Oncogene Proteins c-ret

Back to Details
This is a "connection" page, showing publications ROBERT F GAGEL has written about Proto-Oncogene Proteins c-ret.
ROBERT F GAGEL
Connection Strength
4.132
Proto-Oncogene Proteins c-ret
  1. ONC201 Shows Potent Anticancer Activity Against Medullary Thyroid Cancer via Transcriptional Inhibition of RET, VEGFR2, and IGFBP2. Mol Cancer Ther. 2021 04; 20(4):665-675.
    View in: PubMed
    Score: 0.645
  2. ATF4 Targets RET for Degradation and Is a Candidate Tumor Suppressor Gene in Medullary Thyroid Cancer. J Clin Endocrinol Metab. 2017 03 01; 102(3):933-941.
    View in: PubMed
    Score: 0.491
  3. A novel dual kinase function of the RET proto-oncogene negatively regulates activating transcription factor 4-mediated apoptosis. J Biol Chem. 2015 May 01; 290(18):11749-61.
    View in: PubMed
    Score: 0.429
  4. Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma. Recent Results Cancer Res. 2015; 204:227-49.
    View in: PubMed
    Score: 0.423
  5. Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma. J Intern Med. 2009 Jul; 266(1):99-113.
    View in: PubMed
    Score: 0.289
  6. High resolution array-comparative genomic hybridization profiling reveals deoxyribonucleic acid copy number alterations associated with medullary thyroid carcinoma. J Clin Endocrinol Metab. 2008 Nov; 93(11):4367-72.
    View in: PubMed
    Score: 0.273
  7. Medullary Thyroid Carcinoma in MEN2A: ATA Moderate- or High-Risk RET Mutations Do Not Predict Disease Aggressiveness. J Clin Endocrinol Metab. 2017 08 01; 102(8):2807-2813.
    View in: PubMed
    Score: 0.126
  8. All in the family? Analyzing the impact of family history in addition to genotype on medullary thyroid carcinoma aggressiveness in MEN2A patients. Fam Cancer. 2017 04; 16(2):283-289.
    View in: PubMed
    Score: 0.123
  9. Medullary Thyroid Carcinoma Associated with Germline RETK666N Mutation. Thyroid. 2016 12; 26(12):1744-1751.
    View in: PubMed
    Score: 0.120
  10. Prevalence by age and predictors of medullary thyroid cancer in patients with lower risk germline RET proto-oncogene mutations. Thyroid. 2014 Jul; 24(7):1096-106.
    View in: PubMed
    Score: 0.102
  11. The characterization of pheochromocytoma and its impact on overall survival in multiple endocrine neoplasia type 2. J Clin Endocrinol Metab. 2013 Nov; 98(11):E1813-9.
    View in: PubMed
    Score: 0.097
  12. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011 Jul 01; 29(19):2660-6.
    View in: PubMed
    Score: 0.082
  13. The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors. Endocr Rev. 2010 Aug; 31(4):578-99.
    View in: PubMed
    Score: 0.077
  14. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol. 2010 Feb 10; 28(5):767-72.
    View in: PubMed
    Score: 0.075
  15. Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib. Mol Cancer Ther. 2008 May; 7(5):1001-6.
    View in: PubMed
    Score: 0.067
  16. RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors. Thyroid. 2005 Jun; 15(6):531-44.
    View in: PubMed
    Score: 0.054
  17. Pheochromocytoma and medullary thyroid carcinoma: a new genotype-phenotype correlation of the RET protooncogene 891 germline mutation. J Clin Endocrinol Metab. 2004 Aug; 89(8):4142-5.
    View in: PubMed
    Score: 0.051
  18. Genetic testing in endocrinology: lessons learned from experience with multiple endocrine neoplasia type 2 (MEN2). Growth Horm IGF Res. 2004 Jun; 14 Suppl A:S150-7.
    View in: PubMed
    Score: 0.051
  19. Lessons learned from the management of a rare genetic cancer. N Engl J Med. 2003 Oct 16; 349(16):1566-8.
    View in: PubMed
    Score: 0.049
  20. Promiscuity of pre-mRNA spliceosome-mediated trans splicing: a problem for gene therapy? Hum Gene Ther. 2001 Jul 20; 12(11):1429-41.
    View in: PubMed
    Score: 0.042
  21. Hammerhead ribozyme-mediated inactivation of mutant RET in medullary thyroid carcinoma. Cancer Res. 1999 Aug 15; 59(16):3911-4.
    View in: PubMed
    Score: 0.036
  22. A codon 891 exon 15 RET proto-oncogene mutation in familial medullary thyroid carcinoma: a detection strategy. Mol Cell Probes. 1999 Feb; 13(1):77-9.
    View in: PubMed
    Score: 0.035
  23. Mutational analysis of the GDNF/RET-GDNFR alpha signaling complex in a kindred with vesicoureteral reflux. Hum Genet. 1998 Apr; 102(4):474-8.
    View in: PubMed
    Score: 0.033
  24. Unresolved issues in the genesis and management of multiple endocrine neoplasia type 2. Horm Metab Res. 1997 Mar; 29(3):135-7.
    View in: PubMed
    Score: 0.031
  25. Role of CDKN2C Copy Number in Sporadic Medullary Thyroid Carcinoma. Thyroid. 2016 11; 26(11):1553-1562.
    View in: PubMed
    Score: 0.030
  26. Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab. 1996 Oct; 81(10):3740-5.
    View in: PubMed
    Score: 0.030
  27. RET protooncogene mutational analysis in multiple endocrine neoplasia syndrome type 2B: case report and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1996 Sep; 82(3):288-94.
    View in: PubMed
    Score: 0.030
  28. ret protooncogene mutations and endocrine neoplasia--a story intertwined with neural crest differentiation. Endocrinology. 1996 May; 137(5):1509-11.
    View in: PubMed
    Score: 0.029
  29. The abnormal pentagastrin test. Clin Endocrinol (Oxf). 1996 Feb; 44(2):221-2.
    View in: PubMed
    Score: 0.028
  30. Putting the bits and pieces of the RET proto-oncogene puzzle together. Bone. 1995 Aug; 17(2 Suppl):13S-16S.
    View in: PubMed
    Score: 0.027
  31. RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma. Baillieres Clin Endocrinol Metab. 1995 Jul; 9(3):609-30.
    View in: PubMed
    Score: 0.027
  32. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015 Jun; 25(6):567-610.
    View in: PubMed
    Score: 0.027
  33. Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clin Cancer Res. 2009 Nov 15; 15(22):7061-8.
    View in: PubMed
    Score: 0.018
  34. Management of medullary thyroid carcinoma. Endocrinol Metab Clin North Am. 2008 Jun; 37(2):481-96, x-xi.
    View in: PubMed
    Score: 0.017
  35. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch Surg. 2003 Apr; 138(4):409-16; discussion 416.
    View in: PubMed
    Score: 0.012
  36. Amplification and overexpression of mutant RET in multiple endocrine neoplasia type 2-associated medullary thyroid carcinoma. J Clin Endocrinol Metab. 2003 Jan; 88(1):459-63.
    View in: PubMed
    Score: 0.011
  37. Allelic imbalance of the mutant and wild-type RET allele in MEN 2A-associated medullary thyroid carcinoma. Oncogene. 2001 Nov 22; 20(53):7809-11.
    View in: PubMed
    Score: 0.011
  38. [Germline mutations of the ret proto-oncogene in Chilean patients with hereditary and sporadic medullary thyroid carcinoma]. Rev Med Chil. 2001 Jul; 129(7):713-8.
    View in: PubMed
    Score: 0.010
  39. Duplication of the mutant RET allele in trisomy 10 or loss of the wild-type allele in multiple endocrine neoplasia type 2-associated pheochromocytomas. Cancer Res. 2000 Nov 15; 60(22):6223-6.
    View in: PubMed
    Score: 0.010
  40. Cortical-sparing adrenalectomy for patients with bilateral pheochromocytoma. Surgery. 1996 Dec; 120(6):1064-70; discussion 1070-1.
    View in: PubMed
    Score: 0.008
  41. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA. 1996 Nov 20; 276(19):1575-9.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.